Type-2-diabetes alters CSF but not plasma metabolomic and AD risk profiles in vervet monkeys
Kylie Kavanagh, Stephen M. Day, Morgan C. Pait, William R. Mortiz, Christopher B. Newgard, Olga Ilkayeva, Donald A. McClain, Shannon L. Macauley
This study shows that type 2 diabetes in vervet monkeys alters cerebrospinal fluid metabolites and amyloid levels, but not plasma metabolites or AD risk profiles.
Frontiers in Neuroscience · Aug 28, 2019Peer-reviewedNeuroscience